肺癌筛查成本效益实施的关键参数
本文综述了低剂量CT肺癌筛查的成本效益关键因素,包括筛查人群选择、参与率、筛查间隔、肺结节管理及临床工作流程,并指出基于英国成本的靶向筛查模型多场景在支付阈值内,未来需研究个体化筛查间隔及医疗资源负担。
要点
- 筛查人群选择、参与率和筛查间隔是影响成本效益的核心可调因素。
- 肺结节管理方法和临床工作流程对总成本有重要影响。
- 需量化并管理LDCT筛查对医疗基础设施和人员的负担。
局限性
- 原文未报告具体研究设计细节,如系统检索范围或纳入文献数量。
- 模型结论主要基于英国成本数据,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
It is now widely accepted that lung cancer screening through low-dose computed tomography (LDCT) results in fewer diagnoses at a late stage, and decreased lung cancer mortality. Whilst reducing deaths from lung cancer is an essential prerequisite, this must be balanced against the considerable economic costs accumulated in screening. Multiple health economic models have shown substantial variation in cost per Quality-Adjusted Life Year (QALY), partly driven by the healthcare costs in the country concerned and partly by other modifiable programme components. Recent modelling using UK costs and a targeted approach suggest that most scenarios are within the willingness to pay threshold for the UK. However, identifying the most clinically and cost-effective programme is a priority to minimise the total financial impact. Programme components that influence cost-effectiveness include the method of selection of the eligible population, the participation rate, the interval between rounds of screening, the method of pulmonary nodule management, and the approach to clinical work up. Future research will clarify if a personalised approach to screening, using baseline and subsequent risk to define screening intervals is more cost-effective. The burden of LDCT screening on the medical infrastructure and workforce has to be quantified and carefully managed during implementation.
引用
- Morgan, Baldwin. Important parameters for cost-effective implementation of lung cancer screening. Br J Radiol. 2023. PMID: 36607805. doi:10.1259/bjr.20220489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。